Haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based cancer therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit the unique therapeutic opportunities they provide.
- Pavan Bachireddy
- Ute E. Burkhardt
- Catherine J. Wu